1-154172972-G-A
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM1PM2PM5PP2PP3_ModeratePP5_Very_Strong
The NM_152263.4(TPM3):c.502C>T(p.Arg168Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R168G) has been classified as Pathogenic.
Frequency
Consequence
NM_152263.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TPM3 | NM_152263.4 | c.502C>T | p.Arg168Cys | missense_variant | 5/10 | ENST00000651641.1 | NP_689476.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TPM3 | ENST00000651641.1 | c.502C>T | p.Arg168Cys | missense_variant | 5/10 | NM_152263.4 | ENSP00000498577 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:5Other:1
not provided, no classification provided | literature only | TPM3 homepage - Leiden Muscular Dystrophy pages | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 28, 2022 | Published functional studies demonstrate a decreased affinity for actin and reduced calcium-induced ATPase activation (Robaszkiewicz et al., 2012); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24692096, 24642510, 24456932, 20301436, 12467750, 32675003, 22749829, 19181092, 26307083, 18300303, 20554445, 24095155, 24507666, 19487656, 24239060, 20179953, 22172422, 23584160, 27363342, 29669168, 23886664, 22798622, 21357678, 19953533, 19553118, 17376686, 12601110, 12196661, 12163190, 10619715, 33646172, 33064836, 33652732, 33333461) - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics | Apr 11, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jun 21, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2022 | TPM3: PM2, PM5, PM6, PS4:Moderate, PP3, PP4, PS3:Supporting - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Nov 29, 2016 | - - |
Congenital myopathy 4A, autosomal dominant Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 01, 2013 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Suma Genomics, Suma Genomics | - | A missense variant c.502C>T, p.(Arg168Cys) is observed in exon 5 of TPM3 in heterozygous state. This variant is not observed in the gnomAD database. This variant was reported earlier in the ClinVar database as pathogenic (ClinVar id. 12454). ACMG criteria: PS2, PS3, PM1, PM2_Supporting, PM6 and PP3 - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 07, 2016 | - - |
Congenital myopathy with fiber type disproportion;C5829889:Congenital myopathy 4B, autosomal recessive Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 19, 2024 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 168 of the TPM3 protein (p.Arg168Cys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with congenital myopathy, cap myopathy, nemaline myopathy, and congenital fiber type disproportion (PMID: 18300303, 19487656, 19953533, 20554445, 24095155, 24507666, 24642510, 24692096, 26307083, 27363342). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 12454). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TPM3 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects TPM3 function (PMID: 22749829, 26307083). This variant disrupts the p.Arg168 amino acid residue in TPM3. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 12467750, 17376686, 19553118, 21357678, 22749829, 22798622, 23886664, 24507666, 24692096). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Nemaline myopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | research | Muscle and Diseases Team, Institut de Génétique et Biologie Moléculaire et Cellulaire | Mar 01, 2024 | PS3+PM1+PM2+PM5+PM6+PP2+PP3 - |
Congenital myopathy with fiber type disproportion Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at